SINTX Technologies (SINT)
Manufactures silicon-nitride surgical implants and technical ceramic components.
Something off on this page? Send us feedback.
Manufactures silicon-nitride surgical implants and ceramic components through direct-device sales, OEM supply, contract manufacturing, and grants. Controls processing from powder to finished component at its Salt Lake City facility.
Manufactures medical-grade silicon-nitride implants and components, led by the FDA-cleared SINAPTIC Foot & Ankle Osteotomy Wedge System and the SiNERGY silicon-nitride/PEEK platform. Revenue comes from direct-device sales, spinal OEM supply to CTL Medical, advanced-ceramics contract manufacturing, and grants and contracts. Sales are primarily U.S.-based, while spinal implants made with its material have historical use across Europe, South America, and Asia.
Controls processing from powder through finished component at its Salt Lake City facility, supporting medical-device and technical-ceramics work. Commercializing the cleared device depends on distributor and surgeon adoption, hospital purchasing, reimbursement, and regulatory compliance; active production is concentrated in that certified facility.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $3.6M · Total debt $3.0M · Total assets $10.4M · Shareholders' equity $4.8M
- Revenue
- $452.0K
- Operating income
- −$2.9M
- Net income
- −$2.7M
No dividends on record.
| Institutions | 14.52% | 968.0K shares | |
|---|---|---|---|
| 19 holders · as of Jun 30, 2026 | |||
| Insiders | 13.57% | 904.1K shares | |
| 8 holders · as of Jun 9, 2026 | |||
| Other | 71.91% | 4.79M shares | |
| remainder | |||
6.66M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Lytton Laurence W.Insider | 9.49% | 632,633 | filed Jun 9, 2026 |
Bleichroeder LPInstitution | 7.85% | 523,013 | as of Jun 30, 2026 |
Stonepine Capital Management, LLCInstitution | 3.14% | 209,205 | as of Jun 30, 2026 |
Gregg R. HonigblumInsiderdirector, officer: Chief Investment Officer | 3.02% | 201,067 | filed Dec 9, 2025 |
Veracity Capital LLCInstitution | 1.15% | 76,674 | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Feb 25, 2026 | Christopher Michael Lyons | director | +758 | $2.96 |
| Mar 2, 2026 | Christopher Michael Lyons | director | +7,534 | $2.90 |
| Feb 23, 2026 | Jay M. Moyes | director | +1,000 | $2.91 |
| Feb 18, 2026 | Mark Lewis Anderson | director | +3,000 | $3.02 |
| Dec 8, 2025 | Gregg R. Honigblum | director, officer: Chief Investment Officer | +8,200 | $4.26 |
- Medtronic
Scale spine rival in interbody implants and fusion workflows.
- Stryker
Direct foot-and-ankle device rival with a broad surgical portfolio.
- Zimmer Biomet
Paragon 28 makes it a large foot-and-ankle device rival.
- Johnson & Johnson
DePuy Synthes brings scale to spine and orthopaedic implants.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| SINTX Technologies | $1.78 | +1.14% | $11.2M | — | — | 8.1 | +126.0% |
| Medtronic | $91.43 | −0.35% | $117.44B | 22.6 | 15.2 | 3.1 | +13.7% |
| Stryker | $276.37 | +0.80% | $105.11B | 28.4 | 17.3 | 4.1 | +9.4% |
| Zimmer Biomet | $94.28 | −0.04% | $18.25B | 22.9 | 10.8 | 2.1 | +4.8% |
| Johnson & Johnson | $268.51 | −0.36% | $649.40B | 31.2 | 22.6 | 6.6 | +6.6% |
| Median | 25.7 | 16.2 | 3.6 | +8.0% |